In a mouse model of MI, intracardiac delivery of CMSPKM2 modRNA resulted in upregulation of glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the PPP, leading to enhanced nicotinamide adenine dinucleotide phosphate (NADPH) production, reduced ROS accumulation, and diminished DNA damage as early as two days post-MI. The gene discussed is G6PD; the disease is myocardial infarction.